quantisnow
FeedTopReportsPricing
⌘K
Live feed
06:00:15·217d
INSIDERFiling
Y-mAbs Therapeutics Inc. logo

Director Hamill Laura returned 25,080 shares to the company, closing all direct ownership in the company (SEC Form 4)

YMAB· Y-mAbs Therapeutics Inc.
Health Care
Original source

Companies

  • YMAB
    Y-mAbs Therapeutics Inc.
    Health Care

Recent analyst ratings

  • Apr 22UpdateBofA Securities$3.00
  • Nov 18UpdateOppenheimer$23.00
  • Aug 16UpdateCantor Fitzgerald$20.00
  • Jun 28UpdateTruist$21.00
  • May 10UpdateWedbush$13.00
  • Apr 3UpdateGuggenheim-

Related

  • SEC210d
    SEC Form 15-12G filed by Y-mAbs Therapeutics Inc.
  • INSIDER217d
    Director Wg Biotech Aps closing all direct ownership in the company (SEC Form 4)
  • INSIDER217d
    SEC Form 4 filed by SVP, Danyelza Bus. Unit Head Gentilcore Douglas J
  • INSIDER217d
    Director Gill David N returned $50,095 worth of shares to the company (30,905 units at $1.62), closing all direct ownership in the company (SEC Form 4)
  • INSIDER217d
    Director Tyagi Ashu returned 25,080 shares to the company, closing all direct ownership in the company (SEC Form 4)
  • INSIDER217d
    CHIEF BUSINESS OFFICER Gad Thomas returned 60,235 shares to the company, closing all direct ownership in the company (SEC Form 4)
  • INSIDER217d
    EVP, CFO and Treasurer Pfreundschuh Peter P. returned 77,800 shares to the company, closing all direct ownership in the company (SEC Form 4)
  • INSIDER217d
    PRESIDENT & CEO Rossi Michael J returned 129,101 shares to the company, closing all direct ownership in the company (SEC Form 4)
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022